Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.69 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.69 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.65 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | RECQL | P46063 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | PLEC | Q15149 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 5/20 | 0.69 |
| ▸ | DRD3 | P35462 | 5/20 | 0.69 |
| ▸ | HTR2B | P41595 | 5/20 | 0.69 |
| ▸ | HTR6 | P50406 | 5/20 | 0.69 |
| ▸ | HTR2A | P28223 | 5/20 | 0.69 |
| ▸ | HTR1A | P08908 | 4/20 | 0.69 |
| ▸ | DRD4 | P21917 | 4/20 | 0.69 |
| ▸ | DRD5 | P21918 | 4/20 | 0.69 |
| ▸ | HTR1D | P28221 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29050655 | 0.97 | MEN1 (0.76) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL1162252 | 0.96 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL29473364 | 0.96 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL183687 | 0.96 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL1371966 | 0.96 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL11533855 | 0.96 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| SCHEMBL12951376 | 0.96 | KDM4E (0.80) | KDM4EMEN1KMT2AMAPTRECQL | |
| Hydrochloric Acid SCHEMBL31443171 | 0.95 | KDM4E (0.79) | KDM4EMEN1KMT2AMAPTRECQL | |
| Water SCHEMBL11245600 | 0.95 | KDM4E (0.79) | KDM4EMEN1KMT2AMAPTRECQL | |
| Ammonia Solution, Strong SCHEMBL5792359 | 0.95 | KDM4E (0.79) | KDM4EMEN1KMT2AMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135638-A1 | Process for the manufacture of lysergic acid | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2007-06-14 | — | — | US | disclosed |
| EP-1718644-A1 | PROCESS FOR THE MANUFACTURE OF LYSERGIC ACID | IVAX Pharmaceuticals s.r.o. (CZ) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082902-A1 | PROCESS FOR THE MANUFACTURE OF LYSERGIC ACID | IVAX PHARMACEUTICALS S.R.O. (CZ) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135638-A1 | Process for the manufacture of lysergic acid | LPAR5, LPAR2, LPAR1 | ADRB2 958/4885ADRB1 702/4885ADRA2A 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.